Progenics (PGNX) Gets a Buy Rating from CIM Securities

CIM Securities analyst Kumaraguru Raja maintained a Buy rating on Progenics (NASDAQ: PGNX) on September 13 and set a price target of $13. The company’s shares closed on Friday at $5.62, close to its 52-week low of $5.01.

According to, Raja is a 1-star analyst with an average return of -2.6% and a 55.0% success rate. Raja covers the Healthcare sector, focusing on stocks such as Acer Therapeutics Inc, Tonix Pharma, and Histogenics.

Progenics has an analyst consensus of Strong Buy, with a price target consensus of $14.

See today’s analyst top recommended stocks >>

Based on Progenics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.17 million. In comparison, last year the company had a GAAP net loss of $16.64 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.